Cargando…

Hashimoto’s Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System

SIMPLE SUMMARY: Thyroid nodules in patients with Hashimoto’s thyroiditis (HT) have a high prevalence of equivocal cytology, especially category III of the Bethesda system. The aim of this study was to evaluate the risk of malignancy (RoM) in category III thyroid nodules in patients with and without...

Descripción completa

Detalles Bibliográficos
Autores principales:	Słowińska-Klencka, Dorota, Popowicz, Bożena, Klencki, Mariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025593/ https://www.ncbi.nlm.nih.gov/pubmed/35454876 http://dx.doi.org/10.3390/cancers14081971

Ejemplares similares

Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2022)

Low reproducibility of equivocal categories of the Bethesda System for Reporting Thyroid Cytology makes the associated risk of malignancy specific to the diagnostic center
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2021)

Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2023)

Validation of Four Thyroid Ultrasound Risk Stratification Systems in Patients with Hashimoto’s Thyroiditis; Impact of Changes in the Threshold for Nodule’s Shape Criterion
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2021)

Real-Time Ultrasonography and the Evaluation of Static Images Yield Different Results in the Assessment of EU-TIRADS Categories
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2023)

Diagnostic Value of Six Thyroid Imaging Reporting and Data Systems (TIRADS) in Cytologically Equivocal Thyroid Nodules
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2020)

The influence of fine-needle aspiration biopsy of the thyroid gland on the size of the examined nodule and its ultrasound image
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2012)

Usability of EU-TIRADS in the Diagnostics of Hürthle Cell Thyroid Nodules with Equivocal Cytology
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2020)

The Presence of Hypoechoic Micronodules in Patients with Hashimoto′s Thyroiditis Increases the Risk of an Alarming Cytological Outcome
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2021)

Thyroid nodules with Hürthle cells: the malignancy risk in relation to the FNA outcome category
por: Słowińska-Klencka, D., et al.
Publicado: (2019)

Repeat FNA Significantly Lowers Number of False Negative Results in Patients with Benign Nodular Thyroid Disease and Features of Chronic Thyroiditis
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2014)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

The predictive value of sonographic images of follicular lesions – a comparison with nodules unequivocal in FNA – single centre prospective study
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2016)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy*
por: Lourdes Ng, Jennifer, et al.
Publicado: (2023)

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
por: Almahari, Sayed Ali, et al.
Publicado: (2019)

Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
por: Zahid, Adnan, et al.
Publicado: (2021)

Surgical Outcome and Malignant Risk Factors in Patients With Thyroid Nodule Classified as Bethesda Category III
por: Huang, Jianhao, et al.
Publicado: (2021)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype
por: Yoo, Won Sang, et al.
Publicado: (2020)

Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center
por: Godoi Cavalheiro, Beatriz, et al.
Publicado: (2017)

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital
por: Al Dawish, Mohamed, et al.
Publicado: (2020)

Thyroid Cancer Detection Rate and Associated Risk Factors in Patients with Thyroid Nodules Classified As Bethesda Category III
por: Mileva, Magdalena, et al.
Publicado: (2018)

The Prediction of Malignancy Risk in Thyroid Nodules Classified as Bethesda System Category III (AUS/FLUS) and the Role of Ultrasound Finding for Prediction of Malignancy Risk
por: Alshahrani, Awad S, et al.
Publicado: (2021)

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results
por: Chiang, Pi-Ling, et al.
Publicado: (2023)

Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules
por: Jin, Xiaobing, et al.
Publicado: (2022)

Does the Bethesda category predict aggressive features in differentiated thyroid cancer?
por: Lima, Ana Rafaela Lopes Reis, et al.
Publicado: (2019)

Patients with III and IV category of the Bethesda System under levothyroxine non-suppressive therapy have a lower rate of thyroid malignancy
por: Kaliszewski, Krzysztof, et al.
Publicado: (2019)

Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients
por: Cho, Yoon Young, et al.
Publicado: (2021)

Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF(V600E) Mutation
por: Chirayath, Shiga Rappai, et al.
Publicado: (2019)

Intraoperative frozen section can be reduced in thyroid nodules classified as Bethesda categories V and VI
por: Huang, Jing, et al.
Publicado: (2017)

Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule
por: Li, Fu, et al.
Publicado: (2019)

The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules()
por: Alqahtani, Saad M., et al.
Publicado: (2022)

The Role of “Critical” Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules
por: Orlando, Giuseppina, et al.
Publicado: (2023)

Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III)
por: Thakur, Shilpa, et al.
Publicado: (2019)

Association of patient characteristics, ultrasound features, and molecular testing with malignancy risk in Bethesda III–V thyroid nodules
por: Talmor, Guy, et al.
Publicado: (2022)

Diagnostic value of thyroid imaging reporting and data system combined with BRAF(V600E) mutation analysis in Bethesda categories III–V thyroid nodules
por: Wu, Liuxi, et al.
Publicado: (2022)

Influence of Hashimoto thyroiditis on diagnosis and treatment of thyroid nodules
por: Mao, Linfeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_thubl8fcf4j47b2bd0l0elhavn